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25-Hydroxyvitamin D, 3/?-sulphate has been identified in human plasma. The compound was isolated by 
anion-exchange chromatography and following hydrolysis it was characterized by high-performance liquid 
chromatography and gas chromatography-mass spectrometry. The mean concentration of sulphated 25- 
hydroxyvitamin D, in plasma from 60 patients was 16.7 f7.1 ng/ml and the levels often exceeded those 
of the corresponding free compound. The study also shows that unconjugated 25-hydroxvitamin D, is not 
readily sulphated by man in vivo. 
Vitamin D 25-Hydroxyvitamin D Sterol metabolism 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Vitamin D3 is a prehormone in an endocrine 
system for calcium homeostasis in man and the 
metabolism of this secosteroid has been extensively 
investigated (see [l-4]). Several hydroxylated and 
biologically active metabolites have been iden- 
tified, the most potent hormone being 
la,25-dihydroxyvitamin D3. However, little is 
known about the further metabolism and excretion 
of vitamin D3 metabolites in man. So far no con- 
jugates of vitamin D3 or its metabolites have been 
detected in human blood, although sulphated 
forms have been found in milk from lactating 
women [5-g]. Here I report that 25-hydroxy- 
vitamin DJ 3fl-sulphate is a major circulating form 
of vitamin D3 in man. The concentration of the 
sulphate often exceeds that of free 25-hydroxy- 
vitamin D3, previously recognized as the quan- 
titatively major metabolite in blood [l-4]. The 
biosynthesis of the sulphate has not yet been 
elucidated. However, as demonstrated here, the 
parent compound is not readily conjugated in vivo, 
indicating formation from a sulphated precursor. 
The results suggest an important role of sulphates 
in the metabolism of vitamin D3 in man. 
Steroid conjugation Sulfate ester Human plasma 
2.1. Reference compounds 
Unlabelled 25-hydroxyvitamin D3 was a kind 
gift from Roche-Producter AB, Sweden and 
25-[23,24-3H(n)]hydroxyvitamin D3 (90 Ci/mmol) 
was from the Radiochemical Centre (Amersham, 
England). 3H-labelled 25-hydroxyvitamin D3 
monosulphate was prepared by reacting the 
radioactive free compound with pyridine-sulphur 
trioxide in pyridine for 2 min at room temperature 
[9]. The product was purified by chromatography 
on TEAP-LH-20 (see below). Radioactivity was 
determined in an LKB/Wallac 1215 Rackbeta 
liquid scintillation counter with Instagel as scin- 
tillation liquid. 
2.2. Plasma samples 
Blood from human subjects was collected in 
heparinized tubes and centrifuged immediately. 
The plasma was separated and stored at -20°C 
until analyzed. 
2.3. Analytical procedure 
Potential conjugated metabolites of vitamin D3 
were extracted from plasma (5 ml, diluted with 
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0.5 M aqueous triethylamine sulphate) [lo] on a 
column (1 x 0.8 cm) of octadecylsilane (ODS)- 
bonded silica (preparative Cl& Waters Associates) 
at 64’C [lo-121. Steroid conjugates were eluted 
with 10 ml of 65% aqueous methanol prior to elu- 
tion of unconjugated metabolites of vitamin D3 
with hexane/chloroform [12]. The conjugates were 
then separated into glucuronides, and mono- and 
disulphates on a column (4 x 0.4 cm) of the 
lipophilic anion exchanger, TEAP-LH-20 (HCO;) 
[ 1; 1,131. The monosulphate fraction was desalted 
on a small ODS-silica column [ll] and steroid 
sulphates were hydrolyzed by solvolysis in 
acidified tetrahydrofuran [ 11, f 31. Liberated com- 
pounds were purified by rechromatography on col- 
umns of TEAP-LH-20 (HCOj’) [11,13] and ODS- 
silica [12] prior to analysis by high-performance 
liquid chromatography (HPLC) and gas chroma- 
tography-mass pectrometry (CC-MS). 
2.4. HPLC and GC-MS analysis 
HPLC was carried out on a column (250 x 
4.5 mm) of LiChrosorb (Hibar, Si 100, IOpm, 
Merck, Darmstadt) with hexane/isopropanol as 
the mobile phase. The pump (Constametric III) 
and the fixed wavelength (254 nm) detector were 
from LDC/Milton Roy, Riviera Beach, FL [12]. 
Repetitive magnetic scanning GC-MS was per- 
formed on a Finnigan 1020 instrument housing a 
fused silica column (25 m x 0.3 mm), coated with 
SE-30 [12]. The oven temperature was pro- 
grammed from 190 to 285°C at a rate of S”C/min. 
3. RESULTS AND DISCUSSION 
3.1. rdeniifica~~~n of ~~-hydroxy~itamin D3 
3-s~~~hate 
HPLC analysis of the solvolyzed monosulphate 
fraction from plasma revealed the presence of a 
UV-absorbing compound with the same retention 
time as authentic 25-hydroxyvitamin D3 (fig. 1). 
The compound was isolated, converted into a 
trimethylsilyl (TSM) ether derivative [12] and 
definitively identified by GC-MS [12]. The forma- 
tion and relative amounts of 2 isomers (pyro and 
isopyro forms), their retention times on an open- 
tubular column coated with SE-30 (32.65 and 
35.25 methylene units, respectively) 1121, and their 
mass spectra were identical to those of the TMS 
ether of the reference compound, 2%hydroxyvita- 
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min D3. The mass spectrometric fragmentation of 
this compound has been discussed 1141. When sol- 
volysis of the sulphate fraction from plasma was 
omitted, no compound corresponding to free 
25-hydroxyvitamin D3 was detected by HPLC or 
GC-MS. The possibility that the conjugate was an 
artefact of the isolation procedure was excluded 
after studies of the chromatographic behaviour of 
3H-labelled 25-hydroxyvitamin D3 added to 
plasma. 
The mobility on TEAP-LH-20 of the compound 
in plasma and hydrolysis by a mild solvolytic pro- 
cedure strongly suggested that 25-hydroxyvitamin 
D3 was conjugated with sulphuric acid. Further 
evidence was obtained by rechromatography of the 
sulphate fraction from plasma on a column of 
Sephadex LH-20 using methanol-chloroform (1: 1) 
containing 0.01 M NaCl as mobile phase [ 1.51. This 
separation system has been widely employed for 
isolation of steroid sulphates [15- 171. About 85 % 
of the compound appeared in the monosulphate 
fraction, as determined by HPLC after solvolysis. 
Fig. 1. HPLC analysis of 25hydroxyvitamin D3 in the 
solvolyzed monosulphate fraction isolated from plasma 
of a healthy man. For comparison, the analysis of the 
unconjugated compound in the nonpolar fraction from 
the same plasma sample is shown. The arrows indicate 
the retention time of the reference compound. The 
equivalent of about 0.3 ml pIasma was injected and the 
peaks represent about LO and 8 ng, respectively. A 
column of LiChrosorb connected to a UV detector was 
used with hexane/isopropanol (97: 3) as mobile phase. 
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The synthesis of 3H-labelled 25-hydrox~itamin 
D3 monosulphate permitted a comparison of reten- 
tion times with the conjugated compound in 
plasma on an HPLC column. As seen in fig.2, the 
intact conjugate from plasma and the ‘H-labelled 
sulphate co-eluted, providing strong evidence that 
the conjugated form of 25-hydrox~itamin D3 in 
plasma is a monosulphate. The identity of the 
HPLC peak was ascertained following solvolysis. 
Since 25hydroxyvitamin D3 has 2 hydroxyl 
groups, the position of the sulphate group was in- 
vestigated. When free 25-hydrox~itamin D3 was 
reacted with acetic anhydride/p~id~ne (1: 1) for 
3 h at room temperature, only the 3-hydroxy 
group was acetylated as demonstrated by HPLC 
and GC-MS [18]. When the reaction was carried 
out with the monosulphate fraction from plasma 
followed by solvolysis (which does not hydrolyse 
acetate groups) more than 90% of the originally 
sulphated 25hydroxyvitamin D3 in plasma was 
recovered as the free compound. Unconjugated 
3H-labelled 25hydroxyvitamin D3 added to the 
sulphate fraction prior to acetylation was detected 
as the 3-acetate (retention time 0.43 relative to that 
of underivatized 25hydroxyvitamin D3 by 
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Fig.2. HPLC analysis of intact Shydroxyvitamin D3 
sulphate isolated from human plasma. Synthesized 3H- 
labelled 25hydroxyvitamin D3 sulphate was added to 
the monosulphate fraction prior to injection and 
radioactivity in 0.5ml fractions of the effluent was 
determined. The column and UV detector were those in 
fig.1, and the mobile phase was hexanelisopropanol 
(I : 1). 
straight-phase HPLC, fig. 1). Thus, 25hydroxy- 
vitamin D3 is sulphated in the 3-position. 
3.2. Concentration in human plasma 
The concentrations of 25hydroxyvitamin D3 
3-sulphate and of the corresponding free com- 
pound in plasma from 10 apparently healthy 
human subjects were determined by HPLC (fig.3). 
Addition of 3H-labelled free reference compound 
following separation of conjugates served to cor- 
rect for degradation and losses during solvolysis 
and further purification. No correction for losses 
prior to solvolysis was made, however, yields of 
the 3H-labelled sulphate added to plasma were 
essentially quantitative. During winter (February) 
the mean concentration of sulphated 25-hydroxy- 
vitamin D3 in plasma was 21.1 f 9.2 ng/ml, which 
was similar to that of the corresponding free com- 
pound (mean 19.8 t 10.1 ng/ml). During summer 
(August) the concentration of the free compound 
was increased in 8 subjects (mean 29.9 -t 9.9 ng/ 
ml), and exceeded the sulphate levels in all subjects 
studied (mean 21.9 + 7.2 ng/ml). Thus, the 
seasonal variation of plasma levels of free 25-hy- 
droxyvitamin D3 previously demonstrated [ 191 and 
also seen here was not observed for the sulphated 
compound, indicating that its formation does not 
directly reflect the levels of the free compound. 
However, statistical evaluation of levels of the free 
and sulphated compound in plasma from 60 pa- 
tients (mean 17.1 + 7.2 ng/ml and 16.7 f 
25-OH-D3 m plasma Cng per ml) 
Fig.3. Concentration (ng/ml) of unconjugated and 
sulphated 25hydroxyvitamin D3 in plasma from (A) 10 
apparently healthy human subjects (age 26-35 years) 
and (B) from 60 patients (age 18-82 years). Plasma 
samples were collected from men (squares) and women 
(circles) during the winter (unfill~ symbols) and 
summer (filled symbols) season. CorreIation coefficient 
was 0.52 for both groups and y = 7.48 + 0.54x [ZO]. 
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Fig.4. Concentration @g/ml) of unconjugated (open 
circles) and suiphated (filled circles) ~5-hydroxyvitamin 
I33 in plasma of a woman given orally 250-375 pg of 
25-hydroxyvitamin Dj daily. 
7.0 ng/ml, respectively) provided strong evidence 
for a relatjonship between the 2 compounds 
(fig.3). Great differences in concentrations of the 
2 compounds have been observed in plasma from 
a few subjects, e.g. the levels of the free and 
sulphated 25-hydroxyvitamin D3 in plasma from a 
4-month-ofd child (given vitamin D2 as supple- 
ment) were 0.7 and 12.6 ngfml, respective&. The 
significance of this result is not yet understood. 
3.3. Possible origin in man 
The biosynthesis of 25hydroxyvitamin D3 
J-sulphate in man is not known. In analogy with 
other steroid metabolites, snlphation of 25hy- 
droxyvitamin D3 in the liver might be expected. 
Sulphation of vitamin Dz has been demonstrated 
following incubation with rat liver homogenates 
1211. However, when 25-hydrox~~tamin D3 was 
administered orahy to 2 women with hypocalcemia 
no significant increase of concentrations of the 
sulphated compound in plasma was observed 
(fig.4). These results show that 25hydroxyvitamin 
DJ is not readily sulphated in vivo and indicate that 
25hydroxyvitamin D3 sulphate may be formed 
from a sulphated precursor, Cholesterol sulphated 
in the 3-position is widely distributed in the body 
1221, and may be considered as a potentiaf precur- 
sor [22]. Formation from this compound could 
possibly explain the previous failure of detecting 
the sulphate following administration of radio- 
Iabelled vitamin D3- A dietary source of the com- 
pound or its precursor cannot be excluded, and 
vitamin D3 sulphate has previously been detected 
in significant amounts in dairy milk f5,6]. 
Vitamin D3 sulphate has also been found in milk 
from lactating women [5-S] but its proposed role 
in preventing rickets in breast-fed infants has been 
questioned [23,24]. Recent studies have shown that 
vitamin D3 (and Dz) sulphate possesses little or no 
biological activity [25-273. In an early study, 
25-hydroxyvitamin D3 sulphate was detected as a 
minor component in milk from women f6]. When 
reanalyzed by the same procedure as described 
here for plasma, levels in milk collected from 4 
women a few days after delivery were much lower 
than in plasma and beIow the detection limit 
(<I ng/ml) in all samples. Therefore, it does not 
seem likely that 25hydroxyvitamin D3 sulphate is 
the ‘antirachitic agent’ in human milk. 
This study has shown that the sulphate of 
25-hydroxyvitamin D:, is a quantitatively impor- 
tant form of secosteroids in man. Whether it 
possesses biological activity, reflects the presence 
of a new biosynthetic pathway to hydroxyfated 
vitamin D3, or is an inactive excretion product re- 
mains to be established. 
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